GSE119424 GSE120214 TBXT brachyury inhibition 1 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE119424_GSE120214_TBXT_brachyury inhibition_1_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE119424_GSE120214_TBXT_brachyury inhibition_1_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE119424_GSE120214_TBXT_brachyury inhibition_1_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE119424_GSE120214_TBXT_brachyury inhibition_1_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

POU class 3 homeobox 3

Gene

MT-CO2 pseudogene 12

Gene

dehydrogenase/reductase X-linked

Gene

TMPO antisense RNA 1

Gene

MT-ATP6 pseudogene 1

Gene

Morf4 family associated protein 1 like 2

Gene

deleted in lymphocytic leukemia 2

Gene

MT-ND2 pseudogene 28

Gene

NIPBL divergent transcript

Gene

fer-1 like family member 4 (pseudogene)

  • Gene

    POU class 3 homeobox 3


  • Gene

    MT-CO2 pseudogene 12


  • Gene

    dehydrogenase/reductase X-linked


  • Gene

    TMPO antisense RNA 1


  • Gene

    MT-ATP6 pseudogene 1


  • Gene

    Morf4 family associated protein 1 like 2


  • Gene

    deleted in lymphocytic leukemia 2


  • Gene

    MT-ND2 pseudogene 28


  • Gene

    NIPBL divergent transcript


  • Gene

    fer-1 like family member 4 (pseudogene)

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.